{
  "created_at": "Tue Oct 05 13:3:40 +0000 2021",
  "id_str": "1445335496138313733",
  "full_text": "AstraZeneca asked U.S. regulators for emergency-use authorization for an antibody drug that earlier this year showed strong efficacy in preventing symptomatic Covid-19, offering a potential alternative in evading the disease https://t.co/Y4WhFIap9a",
  "display_text_range": [
    0,
    248
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/Y4WhFIap9a",
        "expanded_url": "https://on.wsj.com/2ZOoapK",
        "display_url": "on.wsj.com/2ZOoapK",
        "indices": [
          225,
          248
        ]
      }
    ]
  },
  "user": {
    "name": "The Wall Street Journal",
    "screen_name": "WSJ",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/971415515754266624/zCX0q9d5_normal.jpg"
  },
  "retweet_count": 30,
  "favorite_count": 91,
  "possibly_sensitive": false,
  "original_created_at": "Tue Oct 05 10:30:09 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "アストラゼネカ社は、今年初めに症状のあるCovid-19の予防に強い効果を示した抗体医薬品の緊急使用許可を米国の規制当局に申請しました。https://t.co/Y4WhFIap9a"
    },
    {
      "locale": "zh",
      "full_text": "阿斯利康公司要求美国监管机构对一种抗体药物进行紧急使用授权，该药物在今年早些时候显示出预防无症状Covid-19的强大功效，为躲避疾病提供了潜在的替代方案https://t.co/Y4WhFIap9a。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "阿斯利康公司要求美國監管機構對一種抗體藥物進行緊急使用授權，該藥物在今年早些時候顯示出預防無症狀Covid-19的強大功效，爲躲避疾病提供了潛在的替代方案https://t.co/Y4WhFIap9a。"
    }
  ]
}